Please login to the form below

Not currently logged in
Email:
Password:

Lundbeck reports profit fall

Danish drugs manufacturer Lundbeck has posted a 1.6 per cent fall in first-quarter net profit to DKK930m (€124.7m)

Danish drugs manufacturer Lundbeck has posted a 1.6 per cent fall in first-quarter net profit to DKK930m (€124.7m).

The company's revenue increased by 7 per cent to DKK4.1bn (€550m) in the first quarter, however, driven by a positive development of key products: antidepressant Cipralex (escitalopram), Alzheimer's treatment Ebixa (memantine) and Parkinson's treatment Azilect (rasagiline). Lundbeck said the products generated sales growth in the quarter, of 6 per cent, 12 per cent and 15 per cent respectively.

Ulf Wiinberg, chief executive, said: "It has been a good first quarter and several positive pipeline events have improved our long-term outlook."

The company still expects to make full-year sales of up to DKK15.8bn (€2.2bn). Earnings before interest and tax, depreciation and amortisation (EBITDA) is still expected to be up to DKK4.6bn (€616m).

5th May 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Healthcare in a lockdown
Even if patients are getting enough care during the COVID-19 pandemic, are they getting the right care?...
Love in the Time of Coronavirus
Having gone through 4 stages of coping with covid-19: first disbelief, then humour, then creative ways to deal with isolation, and finally the tragic realisation that lives are being lost...
The other side of … multiple sclerosis
No good comes from excluding patients from having a say in their own care. In fact, improving activation (& outcomes) demands it....

Infographics